TRDA
Entrada Therapeutics Inc

200
Mkt Cap
$444.86M
Volume
465,481.00
52W High
$12.93
52W Low
$4.93
PE Ratio
-3.35
TRDA Fundamentals
Price
$12.58
Prev Close
$11.62
Open
$11.43
50D MA
$11.00
Beta
1.27
Avg. Volume
190,549.12
EPS (Annual)
-$3.47
P/B
1.45
Rev/Employee
$167,243.42
$179.87
Loading...
Loading...
News
all
press releases
Kory James Wentworth Sells 7,988 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CFO Kory James Wentworth sold 7,988 shares of the business's stock in a transaction on Wednesday, March 4th. The shares were sold at an...
MarketBeat·13h ago
News Placeholder
More News
News Placeholder
Royce & Associates LP Raises Stock Position in Entrada Therapeutics, Inc. $TRDA
Royce & Associates LP grew its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 54.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·1d ago
News Placeholder
Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised Entrada Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·7d ago
News Placeholder
Entrada Therapeutics (NASDAQ:TRDA) Posts Earnings Results, Beats Estimates By $0.38 EPS
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus...
MarketBeat·9d ago
News Placeholder
Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +290.39% and +11.93%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates
Repligen (RGEN) delivered earnings and revenue surprises of +11.26% and +2.96%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline
Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·16d ago
News Placeholder
Entrada Therapeutics (NASDAQ:TRDA) Given Buy Rating at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday...
MarketBeat·17d ago
News Placeholder
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?
EyePoint (EYPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·17d ago
News Placeholder
Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit
Entrada Therapeutics (NASDAQ:TRDA) used a presentation at Guggenheim's 2026 Emerging Outlook Biotech Summit to outline its pipeline focus on intracellular therapeutics and to preview multiple...
MarketBeat·20d ago
<
1
2
...
>

Latest TRDA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.